BPI 9016Alternative Names: BPI-9016; BPI-9016M
Latest Information Update: 14 Oct 2016
At a glance
- Originator Betta Pharmaceuticals Co Ltd
- Class Antineoplastics; Small molecules
- Mechanism of Action Axl receptor tyrosine kinase inhibitors; Proto oncogene protein c met inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 10 Oct 2016 Betta Pharmaceuticals plans a phase Ib/II trial for Non-small cell lung cancer (Late-stage disease, Metastatic disease, First-line therapy) in China (PO) (NCT02929290)